EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

EQT Sweden

Series A Funding will be used to advance Mosanna's nasal spray therapy through Phase 2 Clinical TrialsBiotech veteran David Weber has been appointed CEO to lead the company through clinical developmentObstructive sleep apnea (OSA) affects nearly 1 billion people globally, with the majority undiagnosed and underserved with current treatment optionsView original content:https://www.prnewswire.co.uk/news-releases/eqt-life-sciences-leads-usd-80-million-series-a-funding-round-in-mosanna-therapeutics-to-advance-sleep-apnea-nasal-spray-302476550.html